hWJ-MSC Reduces IL-1β Gene Expression in Alzheimer's Rat Models

International Journal of Research and Review Pub Date : 2024-07-12 DOI:10.52403/ijrr.20240702

Nita Afriani, E. Darwin, Hirowati Ali

{"title":"hWJ-MSC Reduces IL-1β Gene Expression in Alzheimer's Rat Models","authors":"Nita Afriani, E. Darwin, Hirowati Ali","doi":"10.52403/ijrr.20240702","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to study effect of Wharton's Jelly MSCs regulate IL-1β gene expression and to evaluate the potential of these MSCs as an innovative therapy for Alzheimer's disease;\nMethod: This study was post test only control group design. Male Wistar rats were divided into three groups: Control, AlCl3, and AlCl3 + hWJ-MSC. AlCl3 (300 mg/kg/day) was administered orally for 5 days. hWJ-MSCs (1x106 cells) were injected intraperitoneally on day 11. Brain tissue RNA was isolated using TRIzol®, and cDNA synthesis was conducted. Gene expression was analyzed by real-time PCR;\nResult: The results of this study showed that the average of IL-1β levels in Negative Control, Positive Control and Treatment were 0.536 ± 0.342, 0.804 ± 0.801, 0.694± 0.303;\nConclusion: Our study indicates that human Wharton's Jelly Mesenchymal Stem Cells (hWJ-MSCs) can reduce IL-1β levels in an Alzheimer's disease model, suggesting their potential to alleviate inflammation. Although the decrease was not statistically significant, these findings open new avenues for exploring hWJ-MSCs as a promising therapeutic option for Alzheimer's disease.\n\nKeywords: Alzheimer, hWJ-MSC, IL-1β, AlCl3","PeriodicalId":504363,"journal":{"name":"International Journal of Research and Review","volume":"47 15","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research and Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52403/ijrr.20240702","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to study effect of Wharton's Jelly MSCs regulate IL-1β gene expression and to evaluate the potential of these MSCs as an innovative therapy for Alzheimer's disease; Method: This study was post test only control group design. Male Wistar rats were divided into three groups: Control, AlCl3, and AlCl3 + hWJ-MSC. AlCl3 (300 mg/kg/day) was administered orally for 5 days. hWJ-MSCs (1x106 cells) were injected intraperitoneally on day 11. Brain tissue RNA was isolated using TRIzol®, and cDNA synthesis was conducted. Gene expression was analyzed by real-time PCR; Result: The results of this study showed that the average of IL-1β levels in Negative Control, Positive Control and Treatment were 0.536 ± 0.342, 0.804 ± 0.801, 0.694± 0.303; Conclusion: Our study indicates that human Wharton's Jelly Mesenchymal Stem Cells (hWJ-MSCs) can reduce IL-1β levels in an Alzheimer's disease model, suggesting their potential to alleviate inflammation. Although the decrease was not statistically significant, these findings open new avenues for exploring hWJ-MSCs as a promising therapeutic option for Alzheimer's disease. Keywords: Alzheimer, hWJ-MSC, IL-1β, AlCl3

查看原文本刊更多论文

hWJ-MSC 可减少阿尔茨海默氏症大鼠模型中的 IL-1β 基因表达

研究目的本研究旨在探讨沃顿果冻间充质干细胞对 IL-1β 基因表达的调节作用，并评估这些间充质干细胞作为阿尔茨海默病创新疗法的潜力：本研究采用试验后对照组设计。雄性 Wistar 大鼠分为三组：对照组、AlCl3 组和 AlCl3 + hWJ-MSC 组。第 11 天腹腔注射 hWJ-间充质干细胞（1x106 个）。使用 TRIzol® 分离脑组织 RNA 并进行 cDNA 合成。通过实时 PCR 分析基因表达；结果：研究结果表明，阴性对照组、阳性对照组和治疗组 IL-1β 的平均水平分别为 0.536 ± 0.342、0.804 ± 0.801、0.694± 0.303；结论：我们的研究表明，人沃顿果冻间充质干细胞（hWJ-MSCs）能降低阿尔茨海默病模型中的IL-1β水平，这表明它们具有缓解炎症的潜力。尽管这种降低在统计学上并不显著，但这些发现为探索将hWJ-间充质干细胞作为治疗阿尔茨海默病的一种有前途的选择开辟了新的途径：阿尔茨海默病 hWJ-间充质干细胞 IL-1β 氯化铝

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Research and Review

自引率

0.00%

发文量